Production (Stage)
The Oncology Institute, Inc.
TOI
$3.02
$0.031.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 104.41M | 100.27M | 99.90M | 98.58M | 94.67M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 104.41M | 100.27M | 99.90M | 98.58M | 94.67M |
| Cost of Revenue | 87.16M | 85.63M | 85.54M | 85.55M | 82.70M |
| Gross Profit | 17.25M | 14.64M | 14.37M | 13.03M | 11.97M |
| SG&A Expenses | 25.38M | 24.86M | 26.65M | 27.87M | 28.45M |
| Depreciation & Amortization | 1.78M | 1.71M | 1.57M | 1.52M | 1.49M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 114.32M | 112.20M | 113.75M | 114.94M | 112.64M |
| Operating Income | -9.91M | -11.93M | -13.85M | -16.36M | -17.97M |
| Income Before Tax | -19.59M | -13.18M | -16.11M | -15.48M | -19.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.59M | -13.18M | -16.11M | -15.48M | -19.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.59M | -13.18M | -16.11M | -15.48M | -19.89M |
| EBIT | -9.91M | -11.93M | -13.85M | -16.36M | -17.97M |
| EBITDA | -8.13M | -10.22M | -12.28M | -14.85M | -16.48M |
| EPS Basic | -0.25 | -0.14 | -0.18 | -0.17 | -0.27 |
| Normalized Basic EPS | -0.13 | -0.11 | -0.13 | -0.13 | -0.17 |
| EPS Diluted | -0.25 | -0.15 | -0.18 | -0.17 | -0.27 |
| Normalized Diluted EPS | -0.13 | -0.11 | -0.13 | -0.13 | -0.17 |
| Average Basic Shares Outstanding | 77.10M | 75.66M | 75.52M | 74.75M | 74.23M |
| Average Diluted Shares Outstanding | 77.10M | 75.66M | 75.52M | 74.75M | 74.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |